Natera's gross profit for the
three
months ended in Mar. 2024 was $209 Mil. Natera's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $608 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Natera's gross profit for the
three
months ended in Mar. 2024 was $209 Mil. Natera's Revenue for the
three
months ended in Mar. 2024 was $368 Mil. Therefore, Natera's Gross Margin % for the quarter that ended in Mar. 2024 was 56.72%.
Natera had a gross margin of 56.72% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 11 years, the highestGross Margin % of Natera was 50.78%. The lowest was 33.41%. And the median was 43.17%.
Natera Gross Profit Historical Data
The historical data trend for Natera's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Gross Profit distribution charts can be found below:
* The bar in red indicates where Natera's Gross Profit falls into.
Natera Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Natera's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $608 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Natera's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Natera (NAS:NTRA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Natera had a gross margin of 56.72% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Natera Gross Profit Related Terms
Thank you for viewing the detailed overview of Natera's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 